CC 3052

a water-soluble analog of thalidomide; structure in first source

Also Known As:

CC-3052

Networked: 5 relevant articles (2 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Carboxylic Acids: 973
  - Carbocyclic Acids
    - Phthalic Acids: 1
      - Phthalimides: 12
        Thalidomide: 4688
        CC 3052: 5
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperidines: 17
    - Piperidones: 37
      - Thalidomide: 4688
        CC 3052: 5
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Isoindoles: 18
      - Phthalimides: 12
        Thalidomide: 4688
        CC 3052: 5

Experts

1.	Fallows, Dorothy: 2 articles (01/2016 - 07/2011)
2.	Kaplan, Gilla: 2 articles (01/2016 - 07/2011)
3.	Koo, Mi-Sun: 2 articles (01/2016 - 07/2011)
4.	Subbian, Selvakumar: 2 articles (01/2016 - 07/2011)
5.	Tsenova, Liana: 2 articles (01/2016 - 07/2011)
6.	Zeldis, Jerome B: 2 articles (01/2016 - 07/2011)
7.	Dalgleish, A G: 2 articles (09/2000 - 01/2000)
8.	Khetani, Vikram: 1 article (01/2016)
9.	Chung, Sung Kun: 1 article (08/2013)
10.	Lee, You Kyung: 1 article (08/2013)

Related Diseases

1.	Infections 01/01/2016 - "Previously, we showed that the administration of CC-3052, a phosphodiesterase-4 inhibitor (PDE4i), reduced the host inflammatory response during Mycobacterium tuberculosis (Mtb) infection and improved the antimicrobial efficacy of isoniazid (INH) in both the mouse and rabbit models. " 01/01/2000 - "Consistently, the addition of CC-3052 reduced TNF-alpha production in phytohaemagglutinin (PHA) and lipopolysaccharide (LPS)-stimulated whole blood cultures from patients during the primary acute phase of HIV-1 infection. " 01/01/2000 - "We investigated the in vitro effect of the water-soluble, highly stable thalidomide analogue CC-3052 on HIV-1 expression and TNF-alpha production in latently infected promonocytic U1 cells, acutely infected T cells and monocyte-derived human macrophages (MDM), and in mitogen-stimulated ex vivo cultures from patients with primary acute HIV-1 infection. "
2.	Corneal Neovascularization 08/01/2013 - "Topical and subconjunctival administration of thalidomide analogue CC-3052 was found to be effective for the inhibition of corneal neovascularization." 08/01/2013 - "To evaluate the effect of thalidomide analogue CC-3052 on corneal neovascularization in the rabbit model. "
3.	Necrosis 09/01/2000 - "The reduced apoptosis could not be attributed to the ability of CC-3052 to reduce tumour necrosis factor-alpha (TNF-alpha) production, but may be due to its PDE4 inhibitor properties, as it increased [cAMP]i, and mimicked the effect of increasing [cAMP]i using dibutryl cAMP, a membrane-permeable analogue of cAMP. " 01/01/2000 - "The thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis factor-alpha (TNF-alpha) expression in acutely and chronically infected cells in vitro."
4.	Inflammation (Inflammations) 01/01/2016 - "Genome-wide lung transcriptome analysis confirmed the dampening of inflammation and associated network genes that we previously reported with CC-3052. " 07/01/2011 - "tuberculosis infected rabbits with the phosphodiesterase-4 inhibitor CC-3052 plus isoniazid significantly reduced the extent of immune pathogenesis, compared with antibiotic alone, as determined by histologic analysis of infected tissues and the expression of genes involved in inflammation, fibrosis, and wound healing in the lungs. "
5.	Tuberculosis (Tuberculoses) 07/01/2011 - "tuberculosis infected rabbits with the phosphodiesterase-4 inhibitor CC-3052 plus isoniazid significantly reduced the extent of immune pathogenesis, compared with antibiotic alone, as determined by histologic analysis of infected tissues and the expression of genes involved in inflammation, fibrosis, and wound healing in the lungs. "

Related Drugs and Biologics

1.	Type 4 Cyclic Nucleotide Phosphodiesterases
2.	Thalidomide (Thalomid)
3.	Isoniazid (Ftivazide)
4.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
5.	Phosphodiesterase 4 Inhibitors
6.	Mitogens
7.	Lipopolysaccharides
8.	Anti-Bacterial Agents (Antibiotics)